Ubs Group Ag Biovie Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Biovie Inc. stock. As of the latest transaction made, Ubs Group Ag holds 459 shares of BIVI stock, worth $1,271. This represents 0.0% of its overall portfolio holdings.

Number of Shares

459

Previous 22,390 97.95%

Holding current value

$1,271

Previous $11,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.4 - $0.56 $8,772 - $12,281	-21,931 Reduced 97.95%	459 $0
Q1 2024 May 13, 2024	BUY	$0.53 - $1.89 $4,735 - $16,885	8,934 Added 66.39%	22,390 $11,000
Q4 2023 Feb 09, 2024	BUY	$1.22 - $5.24 $12,268 - $52,693	10,056 Added 295.76%	13,456 $16,000
Q3 2023 Nov 09, 2023	SELL	$2.75 - $5.17 $4,042 - $7,599	-1,470 Reduced 30.18%	3,400 $11,000
Q2 2023 Aug 11, 2023	BUY	$4.09 - $8.29 $6,012 - $12,186	1,470 Added 43.24%	4,870 $20,000
Q1 2023 May 12, 2023	SELL	$4.89 - $10.53 $806 - $1,737	-165 Reduced 4.63%	3,400 $27,000
Q4 2022 Feb 08, 2023	BUY	$3.86 - $42.0 $10,178 - $110,754	2,637 Added 284.16%	3,565 $27,000
Q3 2022 Nov 10, 2022	BUY	$1.38 - $25.6 $925 - $17,177	671 Added 261.09%	928 $2,000
Q2 2022 Aug 10, 2022	SELL	$1.44 - $5.04 $2,666 - $9,334	-1,852 Reduced 87.81%	257 $0
Q1 2022 May 16, 2022	SELL	$2.74 - $5.65 $32 - $67	-12 Reduced 0.57%	2,109 $10,000
Q4 2021 Feb 14, 2022	BUY	$4.41 - $6.99 $8,956 - $14,196	2,031 Added 2256.67%	2,121 $10,000
Q3 2021 Nov 15, 2021	SELL	$6.69 - $16.93 $11,901 - $30,118	-1,779 Reduced 95.18%	90 $1,000
Q2 2021 Aug 13, 2021	BUY	$10.57 - $21.61 $19,755 - $40,389	1,869 New	1,869 $32,000

Others Institutions Holding BIVI

# of Institutions

Shares Held

4.73M

Call Options Held

17.2K

Put Options Held

27K

View Full List

About BIOVIE INC.

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $83.6M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

More about BIVI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account